Clinical Trials Browser

Withdrawn × Waldenstrom Macroglobulinemia × Alemtuzumab × Clear all

NCT00081068 2013-01-08

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 2 Withdrawn

Lymphoma, Waldenstrom Macroglobulinemia